| Literature DB >> 30551988 |
Francesco Tecilazich1, Anna Maria Formenti2, Stefano Frara3, Raffaele Giubbini4, Andrea Giustina5.
Abstract
The goal of the clinical management of hypoparathyroidism is to correct acute and chronic hypocalcemia. Treatment of acute hypoparathyroidism via intravenous infusion of Ca++ salts, is necessary only in symptomatic patients, or in asymptomatic patients in the setting of a rapid decrease in ionized Ca++ levels. The treatment cornerstones of chronic hypoparathyroidism are oral supplementation of calcium and/or active vitamin D, that can be associated with dietary restriction of sodium and phosphates, thiazide diuretics, and phosphate binders. Notably, PTH replacement is emerging as a innovative treatment of chronic hypoparathyroidism. rhPTH (1-84) has been shown to safely reduce calcium and vitamin D dosage, and increase serum calcium levels in hypoparathyroid patients. Therefore, rhPTH (1-84) appears to represent a new option in patients with chronic hypoparathyroidism "resistant" to conventional treatment.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30551988 DOI: 10.1016/j.beem.2018.12.002
Source DB: PubMed Journal: Best Pract Res Clin Endocrinol Metab ISSN: 1521-690X Impact factor: 4.690